AstraZeneca plc

08/05/2022 | Press release | Distributed by Public on 08/05/2022 05:01

Calquence tablet formulation approved in the US across current indications

New formulation can be co-administered with gastric acid-reducing agents

Tablet offers equivalent efficacy, safety and consistent dosing compared to current capsule